Ezetimibe to reduce irregular heartbeat after atrial fibrillation ablation
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether ezetimibe, a cholesterol-lowering medication, can help prevent atrial fibrillation (an irregular heartbeat) from coming back after a procedure called catheter ablation. If you are scheduled for your first ablation for persistent atrial fibrillation, this trial may help you maintain a normal heart rhythm.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 80 years old.
- You have been diagnosed with persistent atrial fibrillation (a type of irregular heartbeat) and are scheduled for your first catheter ablation (a procedure to correct the rhythm).
- You have not had a prior catheter ablation for atrial fibrillation.
- You do not have severe heart valve disease that needs surgery or a procedure.
- You have not had a heart attack or stroke in the last 3 months.
- You are not currently participating in another investigational drug or device study.
- You are not pregnant or breastfeeding (if female).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether tirzepatide, a medication for weight and blood sugar, can reduce the chances of atrial fibrillation (an irregular heartbeat) coming back after a heart procedure called catheter ablation in people with overweight or obesity. It may help by addressing weight-related factors that contribute to heart rhythm problems.
This trial tests whether an early procedure (catheter ablation) for atrial fibrillation (AF) can prevent strokes in people with a high risk of stroke. The goal is to see if this treatment is safer and more effective than standard care for patients with other health conditions.
This trial tests if enavogliflozin, a diabetes drug, can help prevent atrial fibrillation (an irregular heartbeat) from coming back after a catheter ablation procedure in people with heart failure. If you've recently had or are planning this procedure, this study may offer a new way to keep your heart rhythm steady.
This study tests advanced technology to improve how atrial fibrillation (AFib) is treated with a heart ablation procedure. It may help patients who are already advised to have AFib ablation by seeing how well the approach works in real clinical practice.
This trial tests whether tirzepatide, a weight-loss and blood-sugar medication, can help prevent atrial fibrillation (AFib) from coming back after a catheter ablation procedure. The study focuses on people with obesity or overweight and heart problems, particularly those with a stiff heart (HFpEF).
This study tests if a specific exercise program can reduce how often atrial fibrillation (a type of irregular heartbeat) happens. If you have non-permanent atrial fibrillation and are willing to follow an exercise plan, this trial might help you manage your condition.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.